Shares of Inovio Pharmaceuticals Inc. (INO) broke into a new 52-week high yesterday, hitting a peak of $12.04.
Shares closed at $11.43 after opening at $11.96 for a move of -4.35%. The company now has a market cap of $1.94 billion.
Investors and traders can learn a lot about a stock’s momentum when it sets a new 52-week high. As an example, bullish investors view a company hitting its highest price in a year as a sign of
momentum and may interpret it as a signal to buy. On the other hand, bearish investors could view a new 52-week high as a signal of the end of a strong run, with the stock possibly peaking out
before an impending period of decline.
For Inovio Pharmaceuticals Inc., the new 52-week high came on volume of 9.89 million. The stock has a float of 169.41 million shares and average daily volume of $n/a. It has a
50-day SMA of $n/a and a 200-day SMA of $n/a.
For a complete fundamental analysis analysis of Inovio Pharmaceuticals Inc., check out Equities.com’s Stock Valuation Analysis report
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Inovio Pharmaceuticals Inc. is based out of Plymouth Meeting, PA and has some 190 employees. Its CEO is J. Joseph Kim.
Inovio Pharmaceuticals Inc. is also a component of the Russell 2000 Index, which is an invaluable tool for any small-cap investor. Consisting of the smaller 2,000 publicly traded companies of the 3,000 largest
companies in America by market cap (which combine to make the broader Russell 3000 index), the Russell 2000 gives the most comprehensive snapshot of the small-cap market of any index out there.
What's more, the Russell 2000 is maintained by Russell Investments, a company committed to using rules-based methodologies to construct unbiased indices that differ from the committee-selected Dow
Jones Industrial Average or S&P 500.
To get more information on Inovio Pharmaceuticals Inc. and to follow the company’s latest updates, you can visit the company’s profile page here:
INO’s Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.com’s
Newsdesk. Also, don’t forget to sign-up for our daily
email newsletter to ensure you don’t miss out on any of our best stories.
All data provided by QuoteMedia and was accurate as of 4:30PM ET.
The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: www.equities.com/disclaimer